Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Tesaro Inc. : TESARO Details Niraparib Phase 1 Clinical Data Presented at the 2013 ASCO Annual Meeting

06/04/2013 | 11:12am US/Eastern
  • A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer
  • A RECIST Response Rate of 50% Was Achieved Across All Dose Levels in Patients With Platinum Sensitive Ovarian Cancer and Germline BRCA Mutations
  • Progression Free Survival Exceeded One Year Among Platinum-Sensitive Ovarian Cancer Responders, Independent of BRCA Mutation Status

CHICAGO, June 4, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), were presented this morning at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

At a dose of 300 milligrams once daily, which represents the dose and schedule that will be utilized in the Phase 3 studies, 75% (three of four patients) with platinum sensitive high grade serous ovarian cancer (HGSOC) achieved a RECIST response. Across all dose levels (30 milligrams to 400 milligrams daily), a RECIST response rate of 46% (6/13 patients) was observed in this population. A RECIST response rate of 50% (5/10 patients) was achieved in patients with platinum sensitive ovarian cancer and germline BRCA mutations. The median duration of response was 431 days for platinum sensitive germline BRCA patients and 444 days for platinum sensitive patients who were not germline BRCA mutation carriers.

In addition, 50% (two of the four patients) with BRCA-positive breast cancer achieved a response. Of the 10 patients with prostate cancer who had evaluable circulating tumor cell count (CTC) levels, seven (70%) had a reduction of > 30% in CTC count.

The ovarian cancer patients enrolled in this study had received a median of six previous regimens of systemic therapy. The breast cancer patients enrolled in this study had received a median of five previous regimens of systemic therapy.

Pharmacokinetic parameters were dose proportional and support once per day oral dosing of niraparib. Niraparib was generally well tolerated at 300 milligrams daily, with a low rate of grade 3/4 toxicities. Thrombocytopenia was identified as the dose-limiting toxicity at a daily dose level of 400 milligrams. The most frequently observed adverse events at the 300 milligram dose included grade 1/2 anemia, fatigue and nausea.   

"We are very pleased with the RECIST response rates observed in both ovarian and breast cancer patients in this trial, particularly at the 300 milligrams once daily dose that will be evaluated in our Phase 3 program," said Dr. Mary Lynne Hedley, President of TESARO. "The results of this study provide further support for the design of our planned Phase 3 trials in ovarian and breast cancer and, in particular, the potential utility of platinum sensitivity and BRCA status as predictors of response to niraparib."

Phase 1 Study Design

This Phase 1 study was designed as a two part trial to determine the maximum tolerated dose and evaluate preliminary antitumor activity, safety/tolerability, pharmacokinetic and pharmacodynamic properties of niraparib. Part A enrolled 60 patients who received a single daily dose of 30 to 400 milligrams of niraparib. Following identification of the maximum tolerated dose, Part B of the study enrolled an additional 40 patients with platinum resistant high grade serous ovarian cancer or castration-resistant prostate cancer who received a single daily dose of 300 milligrams of niraparib. Preliminary results of this study were presented at the ASCO annual meeting in 2011.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. Niraparib is an investigational agent and, as such, has not been approved by any regulatory agencies.TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Form 10-K for the year ended December 31, 2012.

CONTACT: Investor/Media Contact:

         Jennifer Davis

         Sr. Director, Corporate Development & Investor Relations

         +1.781.325.1116 or jdavis@tesarobio.com
distributed by
React to this article
Latest news
Date Title
04:20p Euro Staying Afloat amid Short Position, Carry Trade Unwind
04:13p PHOENIX PETROLEUM PHILIPPINES : launches Amateur Open series
03:58p GERMAN AUTO MAKERS AGREE DEAL TO BUY NOKIA HERE : sources
03:55p RENTRAK : Announces Official Worldwide Box Office Results for Weekend of August 2, 2015
03:45p DC Debuts Robbie Maddison's Pipe Dream
03:24p EMIRATES TELECOMMUNICATION : Glo emerges best network in NCC report
03:23p SERVICOM : NIMASA redeploys directors
03:18p MMI : SA insurance group eyes 25pc more stakes in Kenyan firms
03:18p EQUITY BANK : Three doctors get Sh1.8bn to build Ridgeways hospital
03:03p MOODY : Lebanese banks weighed down by weak economy, Syria conflict
Latest news
Advertisement
Hot News 
ANGLESEY MINING : Final Results and annual report
CAMBIUM GLOBAL TIMBERLAND : Appoints Tony Gardner As Chairman
EQUATORIAL PALM OIL : Non-Executive Buys Shares (DIRECTOR DEALINGS)
ENTEGRA FINANCIAL : posts 2Q profit
FAIR VALUE REIT : DGAP-WpÜG: Takeover Offer ;
Most Read News
08/01 CBB CATTLEMEN BEEF PROMOTION AND RESEARCH BOAR : August 2015
08/01 CORRIDOR OF INVESTMENT : 'CPEC will strengthen trade and investment'
08/01 PAN ASIA MINING : NOTICE OF BOARD OF DIRECTORS’ MEETING
08/01 Government of Canada Supports the Upgrade and Expansion of Highway 1 Near Revelstoke
08/01 St. Louis Post-Dispatch Jim Gallagher column
Most recommended articles
04:20p Euro Staying Afloat amid Short Position, Carry Trade Unwind
03:58p GERMAN AUTO MAKERS AGREE DEAL TO BUY NOKIA HERE : sources
03:00p Yemen Houthi boss tells men to fight on, dismisses loss of Aden
02:47p VEDANTA RESOURCES : Zambian villagers to take on mining firm Vedanta in UK court
02:45p Subaru says suppliers have been told to treat workers fairly